CBIO
Crescent Biopharma, Inc. Common Stock
CBIO
CBIO
30 hedge funds and large institutions have $174M invested in Crescent Biopharma, Inc. Common Stock in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
30
Holders Change
-4
Holders Change %
-11.76%
% of All Funds
0.4%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.01%
New
15
Increased
9
Reduced
5
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
1 |
![]()
Fidelity Investments
Boston,
Massachusetts
|
+$22.8M |
2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$22.4M |
3 |
VA
VR Adviser
New York
|
+$21.9M |
4 |
BI
BVF Inc
San Francisco,
California
|
+$20.9M |
5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$10.4M |
Top Sellers
1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$561K |
2 |
Geode Capital Management
Boston,
Massachusetts
|
-$120K |
3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$80.3K |
4 |
SC
Shay Capital
New York
|
-$74.9K |
5 |
UBS Group
Zurich,
Switzerland
|
-$71.6K |